JAK inhibitors modulate multiple inflammatory pathways by suppressing key cytokines, including IL-6, IL-12, and IL-23, which are implicated in the pathogenesis of both spondyloarthritis and ocular inflammation (9, 35). This evidence concerns the gene IL6 and spondyloarthropathy.